Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist, and Executive Director of Employer Services at the City of Hope Comprehensive Cancer Center in Duarte, CA.

XGEVA (Denosumab) for Lung Cancer: Survival Benefit Suggested by Retrospective Subset Analysis of Key Trial
Fri, 07/15/2011 - 11:42
Author
Howard (Jack) West, MD, Associate Clinical Professor, Medical Oncology, Executive Director, Employer Services, Founder, President and CEO of GRACE

Late last year, I reviewed the approval of the agent XGEVA (denosumab) for patients with skeletal metastases from solid tumors after a randomized phase III trial demonstrated a significant reduction in the rate of development of skeletal-related events compared with the pre-existing standard of Zometa (zoledronic acid) for bone metastases. Importantly, there was no difference in overall survival in the trial as a whole, which included patients with multiple myeloma or solid tumors other than breast cancer and prostate cancer (which were each studied in separate trials). A few months later, the publication of the phase III trial came out, and I actually wrote the accompanying editorial, in which I argued that while the results showing improvement in the endpoint of skeletal-related events, no improvement in survival, marginally better side effect profile, but considerably higher cost made XGEVA a very compelling option but not necessarily an iron-clad unchallanged standard of care when the cost vs. benefit of the agent over Zometa is taken into consideration.

Though I suggested that the results were provocative but not overwhelming from the bird's eye view, I raised the point that if overall survival (OS) were to be improved in a subset of patients, the argument favoring XGEVA would be more compelling, as was noted in a very limited way for patients with NSCLC in the randomized trial:

It is therefore notable that, in a post hoc analysis of OS in the Henry et al11 trial, the HR for NSCLC was statistically superior with denosumab for patients with advanced NSCLC.

Among the many interesting presentations from the World Conference on Lung Cancer in Amsterdam was one by Dr. Giorgio Scagliotti that provides far more detail on the post hoc (retrospective) analysis of patients with lung cancer from this trial. Dr. Weiss provided a summary of the presentation in his great review of that day, but here I'll provide a little more information (primarily just the "picture's worth a thousand words" synopsis).

The overall trial enrolled 1776 patients with a range of cancer types, of which 40% had NSCLC and 9% had SCLC: this large subset of 811 patients with lung cancer served as the basis for this presentation. Looking at the entire group with lung cancer, there was a statistically significant 20% improvement in OS that translated to a 1.2 month prolongation in median OS, as illustrated in the figure below:

os-denosumab-vs-zoledronic-acid

(click on image to enlarge)

In fact, this benefit appeared to be of the same magnitude in patients with NSCLC or SCLC, as shown below:

os-nsclc-denos-vs-zoled os-sclc
Finally, as noted by Dr. Weiss, within the group of patients with NSCLC (702 of the 811 with lung cancer), the benefit seemed comparable in patients with adenocarcinoma vs. squamous cell NSCLC, with a bit higher magnitude of a survival benefit in patients with squamous NSCLC:

os-nsclc-by-histologic-type

As Dr. Weiss suggested in his preliminary discussion of this report, the difference in median survival (in the 1-2 month range for these subsets) appears to underestimate the true benefit, since the curves become more separated out over time.

So what should we make of these data? This was a post hoc subset analysis, which means that the results can't be taken as the gospel: the trial wasn't really designed to answer this question, and you could characterize the positive results as just a "fishing expedition" that happened to show these results that were then highlighted. On the other hand, this is a very large group of patients, and my interpretation is that the survival benefit is likely real even if not 100% proven in a prospective trial, and that it appears to be present for both NSCLC and SCLC, and in both of the main NSCLC subtypes. As Dr. Weiss noted, the mechanism for this apparent survival benefit isn't clear, but there are studies looking into this question in earnest now.

Along with the improvement in SREs and this reported improvement of survival in patients with lung cancer, XGEVA has a similar and really not worse tolerability, a more convenient means of administration (under the skin rather than an IV infusion), and it doesn't require frequent monitoring of kidney function the way Zometa does.

Taken together, my overall take is that there was already a strong if not definitive case to be made for using XGEVA over Zometa in patients with bone metastases from solid tumors, including lung cancer, but cost and question of value were relevant disadvantages that could fairly fit into the equation. However, if we believe that the survival benefit is real and clinically significant (and I do, on both counts, despite the formal caveats of a retrospective analysis of patient subsets), this is enough to convince me that XGEVA is a clearly stronger alternative. In fact, as a therapeutic agent beyond its role as a supportive care agent, XGEVA could frankly be considered a relative bargain in providing a survival benefit of up to a couple of months for a small fraction of the cost of many other agents that we use in this setting (Hello, Avastin!). Though I had expressed some caution about XGEVA in my editorial based on the available data from that analysis, I'm now convinced that the value proposition of it just went way up for the lung cancer community.

Thoughts?

Next Previous link

Previous PostNext Post

Related Content

Forum Discussions

Hi cancersurvivour and welcome to Grace. Congrats on the "previous" aspect of your blood cancer. A haematologist is just the person to keep an eye on you with CT scans. Your...

Thank you for your comments Janine. Makes sense.

Hi survivour, 


 


You have been through a lot already at such a young age, probably too much for someone online to say much. Perhaps your haemotologist and pulmonologist consult to...

Hello and welcome to Grace.  I'm sorry you need to look for this info.  Stage IV rectal cancer survival rate depends on whether cancer is contained regionally or has spread to...

Recent Comments

JOIN THE CONVERSATION
Thank you
By cancersurvivour on Tue, 08/16/2022 - 14:07
Hi survivour, You have been…
By JanineT Forum … on Tue, 08/16/2022 - 11:12
Hi cancersurvivour and…
By cancersurvivour on Tue, 08/16/2022 - 09:30
Hi, I'm so glad your dad was…
By JanineT Forum … on Thu, 08/11/2022 - 08:21